In The Know-November 2020

November 2020

Pdf Summary

In the November 2020 edition of Ed’s List, several important studies in the field of gynecologic oncology are summarized. <br /><br />One study focuses on the use of CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy, demonstrating its potential for targeted gene editing in tumors. Another study evaluates the diagnostic performance of CA125 in primary care for the detection of ovarian and non-ovarian cancers, finding that CA125 is a useful test for ovarian cancer detection in women over 50.<br /><br />In the field of cervical cancer, there are several studies summarized. One study explores the gaps and priority areas for reducing the impact of cervical cancer worldwide, highlighting the need for strategic and evidence-based health services. Another study discusses specific mechanisms of chromosomal instability in high-grade serous ovarian carcinoma, finding that distinct mechanisms of chromosomal instability indicate therapeutic sensitivities.<br /><br />Other studies focus on treatment strategies for recurrent ovarian cancer. One study examines the efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide, finding it to be well-tolerated and associated with clinical benefit. Another study investigates the performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer, recommending sequential immunohistochemistry (IHC) followed by microsatellite instability testing (MSI) as the most sensitive approach.<br /><br />Finally, two reports discuss pregnancy after breast cancer and the impact of pregnancy on breast cancer outcomes in patients with germline BRCA mutations, finding that pregnancy after breast cancer is safe and does not worsen maternal prognosis.<br /><br />These summaries provide a glimpse into the ongoing research and advancements in the field of gynecologic oncology.

Keywords

CRISPR-Cas9 genome editing

lipid nanoparticles

cancer therapy

targeted gene editing

ovarian cancer detection

chromosomal instability

recurrent ovarian cancer

pembrolizumab

Lynch syndrome

pregnancy after breast cancer